Universe Pharmaceuticals Inc Financials

UPC

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE September

This page shows Universe Pharmaceuticals Inc (UPC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 40/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Universe Pharmaceuticals Inc has an operating margin of -16.3%, meaning the company retains $-16 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -34.8% the prior year.

Growth

Universe Pharmaceuticals Inc's revenue declined 22.4% year-over-year, from $23.0M to $17.9M. This contraction results in a growth score of 0/100.

Leverage

100

Universe Pharmaceuticals Inc carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 4.07, Universe Pharmaceuticals Inc holds $4.07 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Universe Pharmaceuticals Inc generated -$5.1M in operating cash flow, capex of $267K consumed most of it, leaving -$5.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

4/9

Universe Pharmaceuticals Inc passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

1.38x

For every $1 of reported earnings, Universe Pharmaceuticals Inc generates $1.38 in operating cash flow (-$5.1M OCF vs -$3.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-10.1x

Universe Pharmaceuticals Inc earns $-10.1 in operating income for every $1 of interest expense (-$2.9M vs $289K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$17.9M

YoY-22.4%

5Y CAGR-10.3%

Universe Pharmaceuticals Inc generated $17.9M in revenue in fiscal year 2025. This represents a decrease of 22.4% from the prior year.

EBITDA

-$2.4M

YoY+68.2%

Universe Pharmaceuticals Inc's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.2% from the prior year.

Free Cash Flow

-$5.3M

YoY+45.2%

Universe Pharmaceuticals Inc generated -$5.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.2% from the prior year.

Net Income

-$3.7M

YoY+57.9%

Universe Pharmaceuticals Inc reported -$3.7M in net income in fiscal year 2025. This represents an increase of 57.9% from the prior year.

EPS (Diluted)

$-8.06

Universe Pharmaceuticals Inc earned $-8.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 98.7% from the prior year.

Cash & Debt

$33.6M

YoY+13.9%

5Y CAGR+27.3%

Universe Pharmaceuticals Inc held $33.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

563,338

Universe Pharmaceuticals Inc had 563,338 shares outstanding in fiscal year 2025. This represents a decrease of 97.6% from the prior year.

Gross Margin

35.3%

YoY+8.9pp

5Y CAGR-10.6pp

Universe Pharmaceuticals Inc's gross margin was 35.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 8.9 percentage points from the prior year.

Operating Margin

-16.3%

YoY+18.5pp

5Y CAGR-49.7pp

Universe Pharmaceuticals Inc's operating margin was -16.3% in fiscal year 2025, reflecting core business profitability. This is up 18.5 percentage points from the prior year.

Net Margin

-20.6%

YoY+17.3pp

5Y CAGR-45.2pp

Universe Pharmaceuticals Inc's net profit margin was -20.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 17.3 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$672K

YoY-77.8%

5Y CAGR+2.9%

Universe Pharmaceuticals Inc invested $672K in research and development in fiscal year 2025. This represents a decrease of 77.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$267K

YoY+28.1%

5Y CAGR+38.8%

Universe Pharmaceuticals Inc invested $267K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 28.1% from the prior year.

UPC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$17.9M-22.4%	$23.0M-28.7%	$32.3M-19.5%	$40.1M-16.3%	$48.0M+56.3%	$30.7M
Cost of Revenue	$11.6M-31.8%	$17.0M-22.9%	$22.0M+36.1%	$16.2M-12.3%	$18.4M+49.4%	$12.3M
Gross Profit	$6.3M+3.8%	$6.1M-41.1%	$10.3M-52.9%	$21.9M-13.6%	$25.3M+79.7%	$14.1M
R&D Expenses	$672K-77.8%	$3.0M-37.6%	$4.9M-36.4%	$7.6M+39.9%	$5.5M+837.3%	$583K
SG&A Expenses	$3.7M+29.7%	$2.9M+9.5%	$2.6M+20.9%	$2.2M-33.8%	$3.3M+93.5%	$1.7M
Operating Income	-$2.9M+63.6%	-$8.0M-102.2%	-$4.0M+43.5%	-$7.0M-151.7%	$13.6M+32.6%	$10.3M
Interest Expense	$289K-5.0%	$305K+60.1%	$190K+17.1%	$162K+59.8%	$102K-17.9%	$124K
Income Tax	N/A	$607K-73.1%	$2.3M+176.4%	$815K-65.4%	$2.4M-7.2%	$2.5M
Net Income	-$3.7M+57.9%	-$8.7M-32.6%	-$6.6M+16.8%	-$7.9M-169.9%	$11.3M+49.8%	$7.6M
EPS (Diluted)	$-8.06	$-626.96	$-1089.21	$-1309.11-36667.3%	$3.58+661.7%	$0.47

Metric	Q3'25	Q3'24	Q2'24	Q3'23	Q2'23	Q3'22	Q1'22	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

UPC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$69.3M+2.0%	$68.0M+62.9%	$41.7M-29.9%	$59.5M-15.1%	$70.1M+143.5%	$28.8M
Current Assets	$53.6M+3.8%	$51.6M+104.3%	$25.3M-39.1%	$41.5M-17.8%	$50.5M+116.8%	$23.3M
Cash & Equivalents	$33.6M+13.9%	$29.5M+458.1%	$5.3M-7.5%	$5.7M-29.3%	$8.1M-19.7%	$10.1M
Inventory	$2.2M+26.3%	$1.7M-48.0%	$3.3M+51.5%	$2.2M-10.4%	$2.5M+29.2%	$1.9M
Accounts Receivable	$13.0M+0.8%	$12.9M+17.2%	$11.0M-27.5%	$15.2M-2.5%	$15.6M+43.2%	$10.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.2M-41.3%	$22.5M+63.2%	$13.8M-43.2%	$24.2M+4.6%	$23.2M+189.4%	$8.0M
Current Liabilities	$13.2M-35.1%	$20.3M+47.7%	$13.8M+5.0%	$13.1M+16.8%	$11.2M+40.1%	$8.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$56.1M+23.4%	$45.5M+62.7%	$28.0M-20.8%	$35.3M-24.8%	$47.0M+125.9%	$20.8M
Retained Earnings	-$13.8M-36.1%	-$10.2M-604.3%	-$1.4M-108.8%	$16.3M-34.9%	$25.1M+82.4%	$13.7M

Metric	Q3'25	Q3'24	Q2'24	Q3'23	Q2'23	Q3'22	Q1'22	Q3'21
Total Assets	$69.3M+2.0%	$68.0M+37.5%	$49.4M+18.5%	$41.7M-40.7%	$70.4M+18.2%	$59.5M-16.6%	$71.4M+1.7%	$70.1M
Current Assets	$53.6M+3.8%	$51.6M+54.0%	$33.5M+32.7%	$25.3M-51.9%	$52.5M+26.5%	$41.5M-19.7%	$51.7M+2.3%	$50.5M
Cash & Equivalents	$33.6M+13.9%	$29.5M+232.9%	$8.9M+67.7%	$5.3M-59.2%	$13.0M+126.8%	$5.7M-59.9%	$14.2M+76.2%	$8.1M
Inventory	$2.2M+26.3%	$1.7M-48.7%	$3.4M+1.3%	$3.3M+16.6%	$2.9M+30.0%	$2.2M-34.8%	$3.4M+37.5%	$2.5M
Accounts Receivable	$13.0M+0.8%	$12.9M-10.3%	$14.4M+30.6%	$11.0M-37.1%	$17.5M+15.4%	$15.2M-19.3%	$18.8M+20.8%	$15.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.2M-41.3%	$22.5M-1.0%	$22.7M+64.9%	$13.8M-40.8%	$23.2M-4.0%	$24.2M+137.2%	$10.2M-55.9%	$23.2M
Current Liabilities	$13.2M-35.1%	$20.3M-1.4%	$20.6M+49.8%	$13.8M-40.8%	$23.2M+77.5%	$13.1M+28.3%	$10.2M-8.9%	$11.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$56.1M+23.4%	$45.5M+70.1%	$26.7M-4.4%	$28.0M-40.6%	$47.1M+33.4%	$35.3M-42.2%	$61.2M+30.1%	$47.0M
Retained Earnings	-$13.8M-36.1%	-$10.2M-245.7%	-$2.9M-103.7%	-$1.4M-109.3%	$15.6M-4.4%	$16.3M-39.1%	$26.8M+6.9%	$25.1M

UPC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.1M+46.9%	-$9.5M-951.3%	$1.1M+185.8%	-$1.3M+36.7%	-$2.1M-133.6%	$6.1M
Capital Expenditures	$267K+28.1%	$208K+371.6%	$44K-52.9%	$94K-78.9%	$445K+758.2%	$52K
Free Cash Flow	-$5.3M+45.2%	-$9.7M-1005.7%	$1.1M+176.9%	-$1.4M+44.2%	-$2.5M-141.2%	$6.1M
Investing Cash Flow	-$342K+5.4%	-$361K-718.0%	-$44K+98.9%	-$3.9M+85.6%	-$27.1M-52141.3%	-$52K
Financing Cash Flow	$9.7M-71.4%	$34.0M+2541.6%	-$1.4M-141.9%	$3.3M-87.5%	$26.6M+5554.1%	$470K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q2'24	Q3'23	Q2'23	Q3'22	Q1'22	Q3'21
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

UPC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	35.3%+8.9pp	26.4%-5.6pp	31.9%-22.6pp	54.5%+1.7pp	52.8%+6.9pp	45.9%
Operating Margin	-16.3%+18.5pp	-34.8%-22.5pp	-12.3%+5.2pp	-17.5%-45.8pp	28.3%-5.1pp	33.4%
Net Margin	-20.6%+17.3pp	-37.9%-17.5pp	-20.4%-0.7pp	-19.7%-43.3pp	23.6%-1.0pp	24.6%
Return on Equity	N/A	N/A	N/A	N/A	24.1%-12.2pp	36.3%
Return on Assets	-5.3%+7.5pp	-12.8%+2.9pp	-15.8%-2.5pp	-13.3%-29.4pp	16.1%-10.1pp	26.2%
Current Ratio	4.07+1.5	2.54+0.7	1.84-1.3	3.17-1.3	4.50+1.6	2.91
Debt-to-Equity	0.23-0.3	0.490.0	0.49-0.2	0.69+0.2	0.49+0.1	0.38
FCF Margin	-29.8%+12.4pp	-42.2%-45.5pp	3.3%+6.8pp	-3.5%+1.7pp	-5.2%-25.0pp	19.8%

Metric	Q3'25	Q3'24	Q2'24	Q3'23	Q2'23	Q3'22	Q1'22	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	4.07+1.5	2.54+0.9	1.63-0.2	1.84-0.4	2.26-0.9	3.17-1.9	5.06+0.6	4.50
Debt-to-Equity	0.23-0.3	0.49-0.4	0.85+0.4	0.490.0	0.49-0.2	0.69+0.5	0.17-0.3	0.49
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

AKANDA CORP AKAN

$2.0M

PRF Technologies Ltd. PRFX

$2.6M

SHUTTLE PHARMACTCLS HLDGS INC SHPH

$3.8M

Redhill Biopharm RDHL

$5.3M

Cbdmd Inc YCBD

$9.6M

Frequently Asked Questions

What is Universe Pharmaceuticals Inc's annual revenue?

Universe Pharmaceuticals Inc (UPC) reported $17.9M in total revenue for fiscal year 2025. This represents a -22.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Universe Pharmaceuticals Inc's revenue growing?

Universe Pharmaceuticals Inc (UPC) revenue declined by 22.4% year-over-year, from $23.0M to $17.9M in fiscal year 2025.

Is Universe Pharmaceuticals Inc profitable?

No, Universe Pharmaceuticals Inc (UPC) reported a net income of -$3.7M in fiscal year 2025, with a net profit margin of -20.6%.

What is Universe Pharmaceuticals Inc's earnings per share (EPS)?

Universe Pharmaceuticals Inc (UPC) reported diluted earnings per share of $-8.06 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Universe Pharmaceuticals Inc's EBITDA?

Universe Pharmaceuticals Inc (UPC) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Universe Pharmaceuticals Inc's gross margin?

Universe Pharmaceuticals Inc (UPC) had a gross margin of 35.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Universe Pharmaceuticals Inc's operating margin?

Universe Pharmaceuticals Inc (UPC) had an operating margin of -16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Universe Pharmaceuticals Inc's net profit margin?

Universe Pharmaceuticals Inc (UPC) had a net profit margin of -20.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Universe Pharmaceuticals Inc's free cash flow?

Universe Pharmaceuticals Inc (UPC) generated -$5.3M in free cash flow during fiscal year 2025. This represents a 45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Universe Pharmaceuticals Inc's operating cash flow?

Universe Pharmaceuticals Inc (UPC) generated -$5.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Universe Pharmaceuticals Inc's total assets?

Universe Pharmaceuticals Inc (UPC) had $69.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Universe Pharmaceuticals Inc's capital expenditures?

Universe Pharmaceuticals Inc (UPC) invested $267K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Universe Pharmaceuticals Inc spend on research and development?

Universe Pharmaceuticals Inc (UPC) invested $672K in research and development during fiscal year 2025.

How many shares does Universe Pharmaceuticals Inc have outstanding?

Universe Pharmaceuticals Inc (UPC) had 563,338 shares outstanding as of fiscal year 2025.

What is Universe Pharmaceuticals Inc's current ratio?

Universe Pharmaceuticals Inc (UPC) had a current ratio of 4.07 as of fiscal year 2025, which is generally considered healthy.

What is Universe Pharmaceuticals Inc's debt-to-equity ratio?

Universe Pharmaceuticals Inc (UPC) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Universe Pharmaceuticals Inc's return on assets (ROA)?

Universe Pharmaceuticals Inc (UPC) had a return on assets of -5.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Universe Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Universe Pharmaceuticals Inc (UPC) had $33.6M in cash against an annual operating cash burn of $5.1M. This gives an estimated cash runway of approximately 80 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Universe Pharmaceuticals Inc's Piotroski F-Score?

Universe Pharmaceuticals Inc (UPC) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Universe Pharmaceuticals Inc's earnings high quality?

Universe Pharmaceuticals Inc (UPC) has an earnings quality ratio of 1.38x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Universe Pharmaceuticals Inc cover its interest payments?

Universe Pharmaceuticals Inc (UPC) has an interest coverage ratio of -10.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Universe Pharmaceuticals Inc?

Universe Pharmaceuticals Inc (UPC) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.